The Health and Pharmaceutical sector’s importance for the economy on both the global and local scenes is continuously increasing. Responding to this, i-MBA introduces a new elective course entitled “Strategic Restructuring in the Healthcare and Life Sciences Sector” from the next academic year, 2017-18. Approaching healthcare and life sciences from a broad perspective, many new opportunities for shared value creation arise, including a new role of public sector healthcare, Public-Private Partnerships, and use of new technologies (big data, social media, e-health…). Innovation and entrepreneurial thinking are needed in order to build new business models focusing on preventive and integrated healthcare, where the role of all players, including public and private providers, pharmaceutical companies and insurance companies, need to be redefined. Strategic restructuring of the Health/Pharma sector is also a key lever to address fiscal and societal challenges.
The new course is addressed to all MBA students but especially to executives of pharma companies, insurance executives, pharmacists and all kinds of healthcare professionals, civil servants, entrepreneurs and investors with an interest in health care innovations.
The course is designed and conducted by Dr. Emmanuel Alexandrakis. Having served over 28 years as an economist, researcher and manager in multinational and local companies, as well as in the public sector, Dr. Alexandrakis has acquired a combined managerial, academic, public policy and strategy analysis experience. In particular, he has served as Associate Director in MSD (Merck Sharp & Dohme) in Greece and Cyprus.
